Alpha-Tocopherol
| Evidence Level: L5 | Predicted Indications: 0 |
Table of Contents
Alpha-Tocopherol: Insufficient Data to Complete Drug Repurposing Assessment
One-Sentence Summary
Alpha-tocopherol, the primary bioactive form of vitamin E, is a fat-soluble antioxidant widely present in foods and supplements. In this Evidence Pack, the TxGNN model generated no novel indication predictions, and there are no registration data in the Singapore market or safety data. The assessment workflow cannot be initiated due to missing core data; it is recommended to complete the data first and then re-execute.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None (no approved registration in Singapore market) |
| Predicted New Indication | None (TxGNN produced no predictions) |
| TxGNN Prediction Score | None |
| Evidence Level | Cannot be determined (no prediction data) |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why Can't This Evaluation Proceed?
Alpha-tocopherol is the most biologically active isoform of vitamin E, functioning primarily as a lipophilic free radical scavenger that exerts antioxidant effects to protect cell membranes from peroxidative damage. According to existing pharmacological knowledge, its applications span research directions including vitamin E deficiency, neuroprotection, and cardiovascular support.
However, this Evidence Pack has three fundamental gaps:
- No TxGNN prediction results: the
predicted_indicationsarray is empty, the core input for drug repurposing assessment does not exist, and subsequent mechanism-of-action correlation analysis, clinical trial matching, and literature evidence cannot be conducted. - No Singapore market registration:
total_licenses = 0, unable to confirm approved indications or current therapeutic positioning, Quick Overview table has no original indications to populate. - Complete lack of safety data: warnings, contraindications, and drug interactions have no data, DG001 has been flagged as Blocking level, and per assessment workflow rules, the preliminary safety evaluation has not passed and should not proceed to indication recommendation stage.
Conclusion and Next Steps
Decision: Hold
Rationale: TxGNN generated no predicted candidate indications, and the safety data gap has been flagged as Blocking level; the existing information is insufficient to support any recommendation decision.
To proceed, the following is needed:
- Confirm DrugBank ID mapping: Query DrugBank to confirm the correct DrugBank ID for ALPHA-TOCOPHEROL, and ensure the drug node exists in the TxGNN knowledge graph
- Re-run TxGNN prediction: using the correct DrugBank ID, re-execute the prediction workflow to generate
predicted_indicationsdata - Obtain Singapore HSA registration data: Query the HSA drug database (https://eservice.hsa.gov.sg/) to confirm whether there are products registered under the ingredient names "tocopherol" or "vitamin E"
- Supplement mechanism of action (MOA): Obtain detailed mechanism descriptions via DrugBank API (DG002, High priority)
- Download package insert and extract safety data: Obtain warnings and contraindications (DG001, Blocking priority); assessment workflow can proceed only after passing preliminary safety evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.